Lupus Science and Medicine (Sep 2022)

Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study

  • Laurent Arnaud,
  • Thierry Martin,
  • Christelle Sordet,
  • Jean Sibilia,
  • Gilles Blaison,
  • María González,
  • Laurent Messer,
  • Aurélien Schlencker,
  • Julia Walther,
  • Olivier Hinschberger,
  • Marc Ardizzone,
  • Etienne Dahan,
  • Anne Dory,
  • Stéphanie Kleinlogel,
  • Aurélia Bramont-Nachman,
  • Lionel Barrand,
  • Isabelle Payen-Revol

DOI
https://doi.org/10.1136/lupus-2022-000700
Journal volume & issue
Vol. 9, no. 1

Abstract

Read online

Objective Among the most significant challenges in SLE are the excessive diagnosis delay and the lack of coordinated care. The aim of the study was to investigate patient pathways in SLE in order to improve clinical and organisational challenges in the management of those with suspected and confirmed SLE.Methods We conducted a cross-sectional study of patients with SLE, healthcare providers and other representative stakeholders. Focus groups were conducted, and based on the collected data the most impactful disruption points in SLE patient pathways were identified. A novel framework to improve individual patient pathways in SLE was developed, discussed and validated during a consensus meeting with representative stakeholders.Results Six thematic clusters regarding disruption in optimal patient pathways in SLE were identified: appropriate and timely referral strategy for SLE diagnosis; the need for a dedicated consultation during which the diagnosis of SLE would be announced, and following which clarifications and psychological support offered; individualised patient pathways with coordinated care based on organ involvement, disease severity and patient preference; improved therapeutic patient education; prevention of complications such as infections, osteoporosis and cancer; and additional patient support. During the consensus meeting, the broader panel of stakeholders achieved consensus on these attributes and a framework for optimising SLE patient pathways was developed.Conclusions We have identified significant disruption points and developed a novel conceptual framework to improve individual patient pathways in SLE. These data may be of valuable interest to patients with SLE, their physicians, health organisations as well as policy makers.